Prediction of intestinal permeability

Advanced Drug Delivery Reviews

Volumn 54, Issue 3, 2002, Pages 273-289

  Egan, William J ^a,b   Lauri, Georgio ^a  

^a Accelrys   (United States)

^b VERTEX PHARMACEUTICALS   (United States)

Author keywords

ADME; ADMET; Computational model; Drug; Intestinal permeability; Passive absorption; QSAR; QSPR

Indexed keywords

COMPUTATION THEORY; METABOLISM; SOLUBILITY;

INTESTINAL PERMEABILITY;

DRUG DOSAGE;

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; GLYCOPROTEIN P; OLIGOPEPTIDE; PROTEIN TYROSINE KINASE; PYRIDONE DERIVATIVE; PYRIMIDINE;

ACCURACY; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG SOLUBILITY; DRUG TRANSPORT; ENZYME INHIBITION; HUMAN; HYDROGEN BOND; HYDROPHILICITY; HYDROPHOBICITY; INTESTINE ABSORPTION; INTESTINE MUCOSA PERMEABILITY; LIPOPHILICITY; MATHEMATICAL MODEL; MEASUREMENT; MOLECULAR SIZE; PASSIVE TRANSPORT; PREDICTION; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; STATISTICAL ANALYSIS; TECHNIQUE; TOXICITY;

EID: 0037204547     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(02)00004-2     Document Type: Article

References (122)

1. The absolute oral bioavailability of selected drugs
2. Drug, meal, and formulation interactions influencing drug absorption after oral administration
3. Effects of food on clinical pharmacokinetics
4. Physicochemical and drug-delivery considerations for oral drug bioavailability
5. Design principles for orally bioavailable drugs
6. Physico-chemical and biological factors that influence a drug's cellular permeability by passive diffusion
7. Review of theoretical passive drug absorption models: Historical background, recent developments and limitations
8. Gastrointestinal absorption of drugs
9. The fluid mosaic model of the structure of cell membranes
10. Human jejunal effective permeability and its correlation with preclinical drug absorption models
11. Partition coefficients and their uses
12. Linear relationships between lipophilic character and biological activity of drugs
13. Lipophilic character and biological activity of drugs. II. Parabolic case
14. Multivariate analysis of experimental and computational descriptors of molecular lipophilicity
15. Computational approaches to lipophilicity: Methods and applications
16. Calculating log P(oct) with no missing fragments; The problem of estimating new interaction parameters
17. Prediction of hydrophobic (lipophilic) properties of small organic molecules using fragmental methods: An analysis of ALOGP and CLOGP methods
18. A practitioner's perspective of the role of quantitative structure-activity analysis in medicinal chemistry
19. A novel method for measuring membrane-water partition coefficients of hydrophobic organic chemicals: Comparison with 1-octanol-water partitioning
20. Molecular structure and drug transport
21. High lipophilicity decreases drug transport across intestinal epithelial cells
22. Patterns of non-electrolyte permeability
23. Molecular forces governing non-electrolyte permeation through cell membranes
24. Shape of membrane permeability-lipophilicity curves: Extension of theoretical models with an aqueous pore pathway
25. Effect of molecular charge on intestinal epithelial drug transport: pH-dependent transport of cationic drugs
26. Absorption prediction from physicochemical parameters
27. Computational methods for the prediction of 'drug-likeness'
28. Property-based design: Optimization of drug absorption and pharmacokinetics
29. Intestinal permeability: Prediction from theory
30. Virtual screening of intestinal drug permeability
31. Prediction of intestinal absorption and blood-brain barrier penetration by computational methods
32. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
33. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases
34. Property distribution of drug-related chemical databases
35. Polar molecular surface properties predict the intestinal absorption of drugs in humans
36. Correlation of drug absorption with molecular surface properties
37. Evaluation of dynamic polar molecular surface area as predictor of drug absorption: Comparison with other computational and experimental predictors
38. Experimental and computational screening models for the prediction of intestinal drug absorption
39. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption
40. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs
41. Prediction of membrane permeability to peptides from calculated dynamic molecular surface properties
42. Cell permeability as a parameter for lead generation in the protein kinase inhibition field
43. Prediction of polar surface area and drug transport processes using simple parameters and PLS statistics
44. Theoretical calculation and prediction of drug transport processes using simple parameters and partial least squares projections to latent structures (PLS) statistics. The use of electrotopological state indices
45. Computation of the physiochemical properties and data mining of large molecular collections
46. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties
47. A widely applicable set of descriptors
48. Hydrogen bond structural group constants
49. Estimation of permeability by passive diffusion through Caco-2 cell monolayers using drugs' lipophilicity and molecular weight
50. Estimation of Caco-2 cell permeability using calculated molecular descriptors
51. Theoretical calculation and prediction of Caco-2 cell permeability using MolSurf parametrization and PLS statistics
52. Theoretical calculation and prediction of intestinal absorption of drugs in humans using MolSurf parametrization and PLS statistics
53. Prediction of human intestinal absorption of drug compounds from molecular structure
54. Quantitative estimation of drug absorption in humans for passively transported compounds on the basis of their physico-chemical parameters
55. Application of MS-WHIM descriptors: 3. Prediction of molecular properties
56. Prediction of drug permeability based on GRID calculations
57. Molecular fields in quantitative structure-permeation relationships: The VolSurf approach
58. VolSurf: A new tool for the pharmacokinetic optimization of lead compounds
59. Theoretical hydrogen bonding parameters for drug design
60. Prediction of drug transport processes using simple parameters and PLS statistics - The use of ACD/logP and ACD/ChemSketch descriptors
61. Toward minimalistic modeling of oral drug absorption
62. Prediction of drug absorption using multivariate statistics
63. Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors
64. Caco-2 cell permeability versus human gastrointestinal absorption: QSPR analysis
65. Structure-property model for membrane partitioning of oligopeptides
66. Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach
67. High-throughput approaches for evaluating absorption, distribution, metabolism, and excretion properties of lead compounds
68. Guest Editorial - Reproducibility, reproducibility, and reproducibility
69. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells
70. Caco-2 monolayers in experimental and theoretical predictions of drug transport
71. Discrimination between drug candidates using models for evaluation of intestinal absorption
72. Applications of the Caco-2 model in the design and development of orally active drugs: Elucidation of biochemical and physical barriers posed by the intestinal epithelium
73. Gastrointestinal absorption of drugs: Methods and studies
74. Ex vivo approaches to predicting oral pharmacokinetics in humans
75. Current methodologies used for the evaluation of intestinal permeability and absorption
76. In vitro methods for the assessment of permeability
77. Estimating intestinal mucosal permeation of compounds using Caco-2 cell monolayers
78. MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening
79. A conditionally immortalized epithelial cell line for studies of intestinal drug transport
80. 1 and Caco-2 cell lines as models for studying intestinal paracellular drug absorption
81. Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds
82. Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats
83. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestine) absorption in man - Fact or myth
84. Comparison of the permeability characteristics of a human colonic epithelial (Caco-2) cell line to colon of rabbit, monkey, and dog intestine and human drug absorption
85. Optimized conditions for the prediction of intestinal drug permeability using Caco-2 cells
86. Evaluation of an accelerated Caco-2 cell permeability model
87. Drug-like properties and the causes of poor solubility and poor permeability
88. Avoiding investment in doomed drugs - Is poor solubility an industry wide problem?
89. Effect of solubilizing excipients on permeation of poorly water-soluble compounds across Caco-2 cell monolayers
90. Guidance in the setting of drug particle size specifications to minimize variability in absorption
91. Carrier-mediated intestinal transport of drugs
92. Minimal molecular determinants of substrates for recognition by the intestinal peptide transporter
93. A family of drug transporters: The multidrug resistance-associated proteins
94. The multidrug resistance protein family
95. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine
96. The gut as a barrier to drug absorption - Combined role of cytochrome P450 3A and P-glycoprotein
97. A general pattern for substrate recognition by P-glycoprotein
98. Structure-activity relationship of P-glycoprotein substrates and modifiers
99. Substrate recognition by P-glycoprotein and the multidrug resistance-associated protein MRP1: A comparison
100. Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein
101. Oral bioavailability of digoxin is enhanced by talinolol: Evidence for involvement intestinal p-glycoprotein
102. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism
103. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics
104. Physicochemical high throughput screening: Parallel artificial membrane permeation assay in the description of passive absorption processes
105. Use of immobilized artificial membrane chromatography for drug transport applications
106. Drug liposome partitioning as a tool for the prediction of human passive intestinal absorption
107. High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes
108. Solid-supported lipid membranes as a tool for determination of membrane affinity: High-throughput screening of a physicochemical parameter
109. HT29-MTX and Caco-2/Tc7 monolayers as predictive models for human intestinal absorption: Role of the mucus layer
110. Outlier detection in multivariate analytical chemical data
111. The Mahalanobis distance
112. The Hat matrix in regression and ANOVA
113. Enhancing the hit-to-lead properties of lead optimization libraries
114. Combinatorial chemistry and high throughput screening in drug discovery and development